Browse the corpus

REFERENCES Furst DE, Keystone EC, Braun J, et al, "Updated Consensus Statement on Biological Agents for the Treatment of Rheumatic Diseases, 2010," Ann Rheum Dis , 2011, 70(Suppl 1)2-36. [PubMed 21339216 ] Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al, "Two-Year Results From an Open-Label, Multicentre, Phase III Study Evaluating the Safety and Efficacy of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Across Different Severity Phenotypes," Ann Rheum Dis , 2011, Aug 21. [PubMed 21859692 ] Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al, "Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome," N Engl J Med , 2009, 360(23):2416-25. [PubMed 19494217 ] NCT 00685373, “Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-Associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease”, Unpublished data. Available at file://clinicaltrials.gov/ct2/show/NCT00685373?term=NCT+00685373&rank=1 . Date Accessed: October 29, 2011 Ruperto N, Brunner H, Horneff G, et al, “Efficacy and Safety of Canakinumab, a Longacting Fully Human Anti-Interleukin-1ß Antibody, in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features: Results From a Phase III Study,” Pediatric Rheumatology , 2011, 9(Suppl 1):021. Ruperto N, Quartier P, Wulffraat N, et al, "A Phase II, Multicenter, Open-Label Study Evaluating Dosing and Preliminary Safety and Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis With Active Systemic Features," Arthritis Rheum , 2012, 64(2):557-67. [PubMed 21953497[ ] Topic 17066 Version 11.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0504-61.234.146.186-658DE962AE-S244013.14]